Alnylam Pharmaceuticals (ALNY)
(Real Time Quote from BATS)
$273.10 USD
+2.10 (0.78%)
Updated Sep 25, 2024 01:22 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Alnylam Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -440.24 | -1,131.16 | -852.82 | -858.28 | -886.12 |
Depreciation/Amortization & Depletion | 97.03 | 85.55 | 89.69 | 74.44 | 54.37 |
Net Change from Assets/Liabilities | 10.76 | -35.55 | -162.82 | -12.70 | 402.38 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 436.61 | 539.89 | 284.26 | 181.59 | 150.94 |
Net Cash From Operating Activities | 104.16 | -541.27 | -641.69 | -614.96 | -278.43 |
Property & Equipment | -62.21 | -72.06 | -76.37 | -70.36 | -140.16 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -269.70 | 246.11 | -192.73 | -359.86 | -270.52 |
Other Investing Activities | -4.44 | -4.69 | -4.20 | -5.30 | -7.00 |
Net Cash from Investing Activities | -336.35 | 169.35 | -273.30 | -435.52 | -417.68 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 147.46 | 259.36 | 246.27 | 299.98 | 853.18 |
Issuance (Repayment) of Debt | 0.00 | 135.39 | 500.00 | 200.00 | -30.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 24.67 | 31.00 | 500.85 | 495.00 | 0.00 |
Net Cash from Financing Activities | 172.13 | 425.75 | 1,247.12 | 994.98 | 823.18 |
Effect of Exchange Rate Changes | 6.39 | -7.43 | -9.02 | 4.92 | -0.08 |
Net Change In Cash & Equivalents | -53.67 | 46.40 | 323.11 | -50.58 | 127.00 |
Cash at Beginning of Period | 868.56 | 822.15 | 499.05 | 549.63 | 422.63 |
Cash at End of Period | 814.88 | 868.56 | 822.15 | 499.05 | 549.63 |
Diluted Net EPS | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 |
Fiscal Year End for Alnylam Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -82.82 | -65.94 | -440.24 | -302.37 | -450.13 |
Depreciation/Amortization & Depletion | 50.18 | 25.49 | 97.03 | 73.06 | 49.53 |
Net Change from Assets/Liabilities | -170.60 | -121.30 | 10.76 | 3.97 | -21.56 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 245.89 | 80.23 | 436.61 | 359.30 | 196.70 |
Net Cash From Operating Activities | 42.64 | -81.52 | 104.16 | 133.95 | -225.46 |
Property & Equipment | -20.99 | -12.97 | -62.21 | -46.90 | -29.81 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -12.69 | -54.65 | -269.70 | -44.35 | -55.12 |
Other Investing Activities | 0.00 | 0.00 | -4.44 | -4.44 | 0.00 |
Net Cash from Investing Activities | -33.68 | -67.62 | -336.35 | -95.69 | -84.93 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 158.64 | 25.86 | 147.46 | 116.57 | 91.77 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 1.77 | 3.05 | 24.67 | 16.33 | 8.00 |
Net Cash from Financing Activities | 160.41 | 28.91 | 172.13 | 132.90 | 99.77 |
Effect of Exchange Rate Changes | -13.06 | -9.94 | 6.39 | -4.51 | 2.05 |
Net Change In Cash & Equivalents | 156.31 | -130.17 | -53.67 | 166.65 | -208.58 |
Cash at Beginning of Period | 814.88 | 814.88 | 868.56 | 868.56 | 868.56 |
Cash at End of Period | 971.19 | 684.72 | 814.88 | 1,035.21 | 659.98 |
Diluted Net EPS | -0.13 | -0.52 | -1.06 | 1.15 | -2.21 |